“…PURPOSE: Human epidermal growth factor receptor 2 positive (HER2+) breast cancers responding poorly to targeted therapy need improved treatment options. miR-101-5p has shown tumor-suppressive properties in multiple cancer forms, and we assessed the effect and mechanism of action of this miRNA in HER2+ breast cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In conclusion, Trastuzumab in combination with FLOT may have curative potential even for metastatic stages of HER-2-positive GC.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In addition, it was observed that the ultrasonic effect on both the HER and OER decreases by elevating the temperature. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Although the role of HER2 amplification and its evaluation methods are well known in breast carcinoma, methods for detection of HER2 amplification in non-small cell lung carcinoma are unclear. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…To target breast cancer cells overexpressing human epidermal receptor 2 (HER2) receptors, anti-HER2 monoclonal antibody (A.Her2) was conjugated to PMBN and afterward loaded with ganoderic acid A (GA-A) as an anti-cancer metabolite. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…PURPOSE: Neoadjuvant therapy (NAT) is considered the standard of care for patients with HER2-positive breast cancer (BC). However, there is no proven survival benefit of NAT compared to adjuvant therapy for the survival of patients with early-stage HER2-positive BC. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer who were previously treated with trastuzumab received trastuzumab every 3 weeks and irinotecan every 2 weeks. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Novel (B,N)-doped three-dimensional (3D) porous graphene–carbon nanotubes (CNTs) can be used as an excellent alkaline and acid tolerant electrocatalyst for both the oxygen reduction reaction (ORR) and the hydrogen evolution reaction (HER). Based on density functional theory, the H and O atoms’ pre-and post-adsorption energy can effectively reduce the reaction energy barrier.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We previously reported that the density of Tumor Microenvironment of Metastasis (TMEM) doorways (portals for cancer cell intravasation and dissemination) is a prognostic biomarker for the development of distant metastasis in hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) patients. We have shown further that Mena(Calc), a mechanistically linked (but independent) biomarker for distant metastasis, is prognostic in some cohorts of triple-negative patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Moreover, the treatment of HER2+ breast cancer is challenging due to heterogeneity. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RESULTS: MiR-620 inhibited ESCC malignancy and suppressed the aerobic glycolysis of ESCC cells via targeting Forkhead box M1 (FOXM1) and human epidermal growth factor receptor 2 (HER2). Moreover, exosomal miR-620 was highly secreted in ESCC and could regulate HFL1 aerobic glycolysis via FOXM1/HER2 signaling. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This study aimed at testing the applicability of the generic change indicators (GCI) model to identify moments of change in the parent during dyadic interventions, as well as to explore, describe and illustrate the therapeutic process through a brief mentalization-informed intervention with a depressive mother and her baby, using video-feedback as its main strategy, which has ample evidence about its effectiveness. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Brain metastases (BMs) are frequent events in patients with HER2-positive metastatic breast cancer (MBC) and are associated with poor prognosis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: There is a concern that HER2-directed systemic therapies, when administered concurrently with stereotactic radiosurgery (SRS), may increase the risk of radiation necrosis (RN). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In this paper, a qualitative study was conducted on Jennifer, an EFL teaching professional at the tertiary level in a Chinese context, to investigate her cognitions regarding her professional development and accompanying facilitating factors in her journey from a novice teacher to a teacher leader with Borg’s model of language teacher cognition as the conceptual basis for subsequent analysis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Non-luminal subtypes are more frequent in endocrine-resistant pts and in metastatic sites (vs. primary tumors), have less benefit from ET, and worse prognosis. Among these, HER2-enriched subtypes are similar to HER2+ tumors and benefit from the addition of anti-HER2 agents (lapatinib) and, for less clear reasons, of ribociclib (unconfirmed data for palbociclib and everolimus). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Triple-negative breast cancer (TNBC) is classically defined by estrogen receptor (ER) and progesterone receptor (PR) immunohistochemistry expression <1% and absence of HER2 amplification/overexpression. HER2-negative breast cancer with low ER/PR expression (1–10%) has a gene expression profile similar to TNBC; however, real-world treatment patterns, chemotherapy response, endocrine therapy benefit, and survival outcomes for the Low-ER group are not well known. 516 patients with stage I-III HER2-negative breast cancer and ER/PR expression ≤10% who were enrolled in a multisite prospective registry between 2011 and 2019 were categorized on the basis of ER/PR expression. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…From all ABC patients, 1,671 HR+/HER2- ABC patients were extracted and enrolled in our study. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A 65-year-old man with mGC was HER-2 positive. Standard trastuzumab, combined with chemotherapy, was given in the first-line therapy and progression-free survival (PFS) was 8 months. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso